10/12
Inconc.
Late treatment study
et al., Pharmacotherapy, doi:10.1002/phar.2467 (Peer Reviewed)
Hydroxych loroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality
Retrospective database analysis with PSM not including COVID-19 severity, finding mortality OR 0.95 [0.62-1.46] for HC Q, and 1.24 [0.70-2.22] for HC Q+AZ. Confounding by indication likely.
death, ↓4.3%, p=0.83
death, ↑20.5%, p=0.46
(odds ratio converted to relative risk)
death, ↑20.5%, p=0.46
(odds ratio converted to relative risk)